Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi⁸,Met(O₂)¹¹]-Substance P.

ABSTRACT: Radiopharmaceutical development hinges on the affinity and selectivity of the biological component for the intended target. An analogue of the neuropeptide Substance P (SP), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[Thi⁸,Met(O₂)¹¹]-SP (DOTA-[Thi⁸,Met(O₂)¹¹]SP), in the theranostic pair [⁶⁸Ga]Ga-/ [²¹³Bi]Bi-DOTA-[Thi⁸,Met(O₂)¹¹]SP has shown promising clinical results in the treatment of inoperable glioblastoma. As the theranostic targeting component, modifications to SP that affect the selectivity of the resulting analogue for the intended target (neurokinin-1 receptor [NK1R]) could be detrimental to its therapeutic potential. In addition to other closely r

SUBMITTER: Suthiram J 

PROVIDER: S-EPMC9916806 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature